Biological Trace Element Research

, Volume 158, Issue 2, pp 219–223

The Protective Effect of Vanadium Against Diabetic Cataracts in Diabetic Rat Model

  • Lei Sun
  • De-Jing Shi
  • Xiang-Chun Gao
  • Shu-Yong Mi
  • Ying Yu
  • Qing Han


The present study was designed to investigate the effect of vanadium in alloxan-induced diabetes and cataract in rats. Different doses of vanadium was administered once daily for 8 weeks to alloxan-induced diabetic rats. To know the mechanism of action of vanadium, lens malondialdehyde (MDA), protein carbonyl content, activity of superoxide dismutase (SOD), activities of aldose reductase (AR), and sorbitol levels were assayed, respectively. Supplementation of vanadium to alloxan-induced diabetic rats decreased the blood glucose levels due to hyperglycemia, inhibited the AR activity, and delayed cataract progression in a dose-dependent manner. The observed beneficial effects may be attributed to polyol pathway activation but not decreased oxidative stress. Overall, the results of this study demonstrate that vanadium could effectively reduce the alloxan-induced hyperglycemia and diabetic cataracts in rats.


Vanadium Diabetes Blood glucose Cataract 


  1. 1.
    Pollreisz A, Schmidt-Erfurth U (2010) Diabetic cataract—pathogenesis, epidemiology and treatment. J Ophthalmol 2010:608751PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Kyselova Z, Stefek M, Bauer V (2004) Pharmacological prevention of diabetic cataract. J Diabet Complicat 18:129–140CrossRefGoogle Scholar
  3. 3.
    Nakamura J, Kasuya Y, Hamada Y et al (2001) Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. Diabetologia 44:480–487PubMedCrossRefGoogle Scholar
  4. 4.
    Chung SS, Chung SK (2003) Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem 10:1375–1387PubMedCrossRefGoogle Scholar
  5. 5.
    Banditelli S, Boldrini E, Vilardo PG et al (1999) A new approach against sugar cataract through aldose reductase inhibitors. Exp Eye Res 69:533–538PubMedCrossRefGoogle Scholar
  6. 6.
    Klein BEK, Klein R, Wang Q et al (1995) Older-onset diabetes and lens opacities. The Beaver Dam Eye Study. Ophthalmic Epidemiol 2:49–55PubMedCrossRefGoogle Scholar
  7. 7.
    Klein BEK, Klein R, Lee KE (1998) Diabetes, cardiovascular disease, selected cardiovascular disease risk factors, and the 5-year incidence of age-related cataract and progression of lens opacities: the Beaver Dam Eye Study. Am J Ophthalmol 126:782–90PubMedCrossRefGoogle Scholar
  8. 8.
    Shindea UA, Sharma G, Xu YJ et al (2004) Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitus. J Trace Elem Med Biol 18:23–32PubMedCrossRefGoogle Scholar
  9. 9.
    Nomura Y, Okamoto S, Sakamoto M et al (2005) Effect of cobalt on the liver glycogen content in the streptozotocin-induced diabetic rats. Mol Cell Biochem 277:127–130PubMedCrossRefGoogle Scholar
  10. 10.
    Gil J, Miralpeix M, Carreras J, Bartrons R (1988) Insulin-like effects of vanadate on glucokinase activity and fructose 2,6-bisphosphate levels in the liver of diabetic rats. J Biol Chem 263:1868–1871PubMedGoogle Scholar
  11. 11.
    Shechter Y (1990) Insulin-mimetic effects of vanadate. Possible implications for future treatment of diabetes. Diabetes 39:1–5PubMedCrossRefGoogle Scholar
  12. 12.
    Lu B, Ennis D, Lai R, Bogdanovic E (2001) Enhanced sensitivity of insulin-resistant adipocytes to vanadate is associated with oxidative stress and decreased reduction of vanadate (+5) to vanadyl (+4). J Biol Chem 276:35589–35598PubMedCrossRefGoogle Scholar
  13. 13.
    Preet A, Gupta B, Yadava PK et al (2005) Efficacy of lower doses of vanadium in restoring altered glucose metabolism and antioxidant status in diabetic rat lenses. J Biosci 30(2):221–230PubMedCrossRefGoogle Scholar
  14. 14.
    Reddy PY, Giridharan NV, Reddy GB (2012) Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. Mol Vis 18:495–503PubMedCentralPubMedGoogle Scholar
  15. 15.
    Pollreisz A, Schmidt-Erfurth U (2010) Diabetic cataract—pathogenesis, epidemiology and treatment. J Ophthalmol. doi:10.1155/2010/608751, ID 608751PubMedCentralPubMedGoogle Scholar
  16. 16.
    Obrosova IG, Chung SSM, Kador PF (2010) Diabetic cataracts: mechanisms and management. Diabetes Metab Res Rev 26:172–180PubMedCrossRefGoogle Scholar
  17. 17.
    Vats V, Yadav SP, Biswas NR et al (2004) Anti-cataract activity of Pterocarpus marsupium bark and Trigonella foenum-graecum seeds extract in alloxan diabetic rats. J Ethnopharmacol 93:289–294PubMedCrossRefGoogle Scholar
  18. 18.
    Zhang S, Chai FY, Yan H et al (2008) Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. Mol Vis 14:862–870PubMedCentralPubMedGoogle Scholar
  19. 19.
    Srivastava SK, Ramana KV, Bhatnagar A (2005) Role of aldose and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26:380–392PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Lei Sun
    • 1
  • De-Jing Shi
    • 1
  • Xiang-Chun Gao
    • 1
  • Shu-Yong Mi
    • 1
  • Ying Yu
    • 1
  • Qing Han
    • 1
  1. 1.Department of OphthalmologyThe Fourth Hospital of Harbin Medical UniversityHarbinPeople’s Republic of China

Personalised recommendations